Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Hope Biosciences

13 clinical trials

Clinical trial
Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease
Status: Recruiting, Estimated PCD: 2025-12-15
Clinical trial
An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Autologous HB-adMSCs for the Treatment of Patients With Parkinson's Disease
Status:
Clinical trial
A Phase II, Open Label, Single-Center, Clinical Trial to Assess Safety and Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease
Status: Completed, Estimated PCD: 2020-11-25
Clinical trial
A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
"A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease"
Status: Completed, Estimated PCD: 2023-02-06
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Status: Terminated, Estimated PCD: 2021-09-30
Clinical trial
Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Patients With Post-COVID-19 Syndrome
Status:
Clinical trial
A Randomized, Double-blinded, Single-center, Phase 2 Efficacy, and Safety Study of Allogeneic HB-adMSCs for the Treatment of Patients With Chronic Post-COVID-19 Syndrome.
Status: Completed, Estimated PCD: 2024-04-02
Clinical trial
"Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Primary Lateral Sclerosis"
Status:
Clinical trial
An Intermediate Size Patient Population Expanded Access IND to Evaluate the Safety of Autologous HB-adMSCs for the Treatment of Patients With Parkinson's Disease.
Status:
Clinical trial
Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
Status: